Sofosbuvir and velpatasvir with or without voxilaprevir in direct-acting antiviral-naïve chronic hepatitis C: patient-reported outcomes from POLARIS 2 and 3.

Zobair M YounossiM StepanovaI M JacobsonAsselah TarikE J GaneE LawitzG R FosterStuart Keith RobertsA J ThompsonB E WillemsT M WelzelB PearlmanI YounossiA RacilaL Henry

Published in: Alimentary pharmacology & therapeutics (2017)

The pan-genotypic regimens with SOF/VEL with or without VOX not only have excellent efficacy and safety, but also significantly positively impact patients' experience both during treatment and after achieving sustained virologic response in DAA-naïve patients with HCV.

Keyphrases

patient reported
hepatitis c virus
end stage renal disease
ejection fraction
newly diagnosed
prognostic factors
peritoneal dialysis
antiretroviral therapy